Opendata, web and dolomites

OUTLIVE SIGNED

OUTLIVE: a disruptive non-invasive ultrasound therapy to treat all patients affected with aortic stenosis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OUTLIVE project word cloud

Explore the words cloud of the OUTLIVE project. It provides you a very rough idea of what is the project "OUTLIVE" about.

death    risks    commercialisation    sick    risk    mark    threatening    game    trust    revolutionary    langevin    strategy    poor    clinical    solutions    jobs    consists    calcifies    innovative    ready    gateway    establishments    entrepreneur    ultrasounds    exceeding    changer    french    ultrasound    device    business    causes    hospital    valve    cardiologists    delivers    scalable    imaging    dramatically    adopters    aortic    thanks    world    complications    heart    image    investor    therapy    immense    context    cardiawave    stenosis    combined    time    care    cumulative    patients    refine    prize    institut    outlive    winner    replacing    intensity    medtech    unlike    function    disease    2030    ce    standard    25    expertise    untreated    blood    physicians    guided    demonstrated    safety    date    solution    sudden    perfusion    age    unmet    treating    opening    stiffens    efficacy    treatment    caused    invasive    accelerate    leader    benefit    relation    million    hegp    created    revenues    valvosoft    narrowing    1bn    plan    market    repair    health    medical    contests    life    gold    body   

Project "OUTLIVE" data sheet

The following table provides information about the project.

Coordinator
CARDIAWAVE 

Organization address
address: 12 RUE ALBERT ROUSSEL
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙563˙750 €
 EC max contribution 2˙494˙625 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIAWAVE FR (PARIS) coordinator 2˙494˙625.00

Map

 Project objective

Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.

 Publications

year authors and title journal last update
List of publications.
2019 D. Suarez Escudero, M. Tanter, M. Pernot
FROM 2D TO 3D REAL-TIME PASSIVE CAVITATION IMAGING OF PULSED CAVITATION ULTRASOUND THERAPY
published pages: , ISSN: , DOI:
2020-01-29
2019 M. Pernot, M. C. Rémond, R. Penot, D. Ladarré, Philippe Mateo, N. Ialy-Radio, D. Suarez, Guillaume Goudot, Wojciech Kwiecinski, Michael Vion, F. Betting, Aurélien Corbel, Ana Fouquier, Sergio Cammarata, Eric Noël, Zahir Larabi, M. Tanter, E. Messas
A new therapeutic device for transthoracic treatment of calcified aortic stenosis
published pages: , ISSN: , DOI:
2020-01-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTLIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OUTLIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

APS (2019)

On-site and On-demand Flexible Packaging System

Read More